Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

Background and aim Current observational studies have compared the effectiveness and
safety of edoxaban with other oral anticoagulants in patients with AF, but the results are still …

BACKGROUND: The very elderly (≥ 80 years) are at high risk of nonvalvular atrial
fibrillation and thromboembolism. Given its recent approval, the comparative effectiveness …

Direct oral anticoagulants (DOACs) represent the cornerstone therapy for cardioembolic
events prevention in patients with nonvalvular atrial fibrillation (NVAF). In practice, the …

Background: Rivaroxaban and amiodarone are commonly used for treating patients with
atrial fibrillation. Drug-drug interactions between rivaroxaban and amiodarone may increase …

Aims Direct oral anticoagulants (DOAC) are progressively replacing vitamin K antagonists in
the prevention of thromboembolism in patients with atrial fibrillation. However, their real …

This report describes major pathomechanisms of disease in which the dysregulation of host
inflammatory processes is a major factor, with cardiovascular disease (CVD) as a primary …

Abstract Background Vitamin‐K antagonists (VKAs) have widely been replaced by non‐VKA
oral anticoagulants (NOACs). This includes Austria, Germany and Switzerland, where as …

Objectives In this prospective, double-blinded, randomized split-mouth study, the local
hemostatic effect of platelet-rich fibrin (PRF) inserted into the extraction socket in patients …

Introduction Treatment adherence and persistence impact the effectiveness of edoxaban for
the prevention of thromboembolism in patients with atrial fibrillation (AF). The objective of …